Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate
Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate
Evogene 2024年第三季度GAAP每股收益$(1.31)，低於$(0.63)的預期，銷售額$180萬，低於$285萬的預期
Evogene (NASDAQ:EVGN) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by 107.94 percent. The company reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $2.85 million by 36.98 percent. This is a 52.32 percent decrease over sales of $3.77 million the same period last year.
Evogene（納斯達克：EVGN）報告每股虧損$(1.31)，低於分析師共識預期$(0.63)107.94%。該公司報告季度銷售額爲$180萬，低於分析師共識預期$285萬36.98%。與去年同期$377萬的銷售額相比，下降了52.32%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間